CELLENVISION COMPANY LIMITED

 

Area: MOST Inno Zone

Booth No: N915

Website: https://www.cellenvission.com.tw/

 

Exhibitor Profile

 

We offer the first commercial Patient-Derived Explants (PDEs) platform to profile cancer immunotherapy response using single-cell functional multi-omics. By analyzing immune–tumor interactions at both single- and multicellular levels across tumor types, we enable lineage-based TiME characterization. Our Patient-Derived Organoids (PDOs) platform reveals rare-cell functional biology and immune context, accelerating discovery in oncology and reproductive medicine. Lung adenocarcinoma is our first focus for predicting metastasis and recurrence.
The features of the Cell Envision SACA monitoring system include:
● Liquid biopsy – Only 4ml of blood is needed for analysis
● Simultaneous analysis of multiple cancer cell types - Circulating tumor cancer cells, cancer cell clusters, immune cells and cancer cell conjugated, and more can be analyzed.
● High accuracy - The predicted success rate is 8 times higher than that of CEA or CA 199 monitoring alone
● Ease of use – Single cancer cells can be isolated to the genetic testing platform

 

Brands

 

CellEnvision

 

Exhibit Products

 

• 

  Precision Medicine Platform : Personalized Immunotherapy and TiME Monitoring

 

Exhibitor Press Release

 

• Innovative Microfluidic Liquid Biopsy System Offers a New Solution for Colorectal Cancer Recurrence 2025-06-18
• Beyond Genomic Testing: A New Immune Response Profiling Platform Aligned with 2025 AACR Trends 2025-06-18

 

 

 

back